Newsroom 2006
Attention Business/Financial Editors:
Neurochem announces resignation of a director
LAVAL, QC, Aug. 18 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)
announced today that Mr. Ronald Nordmann has resigned from the Company's Board
of Directors. Mr. Nordmann joined the Board in 2002. During his tenure, he
served on various committees and acted as the Lead Director for two years, up
to May 2006.
"Ron has been a valued member of Neurochem's Board of Directors," said
Dr. Francesco Bellini, Chairman, President and CEO of Neurochem. "We are
grateful for his professional advice in addition to the counsel he has
generously provided to Neurochem and we wish Ron the very best in the future."
About Neurochem
Neurochem is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(Kiacta(TM)) is currently being developed for the treatment of AA amyloidosis,
for which the Company received an approvable letter from the FDA in August
2006. Tramiprosate (Alzhemed(TM)), for the treatment of Alzheimer's disease,
is currently in Phase III clinical trials in both North America and Europe and
tramiprosate (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused
by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1 (877) 680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4570, lhebert@neurochem.com
